StockData

Amphastar Pharmaceuticals, Inc. (AMPH) stock

AMPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3013% below fair value
$29.10−0.07 (-0.24%)

Close on Nov 17, 2026Market cap $1.24BP/E 17.1Yield –

Amphastar Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Amphastar Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was $114.29M, down 37.1% year over year. For fiscal 2025 it was $140.40M, down 31.7% from the year before. The highest annual figure on record is $205.42M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$140.40M-31.7%
FY2024Dec 31, 2024$205.42M+4.3%
FY2023Dec 31, 2023$196.99M+83.2%
FY2022Dec 31, 2022$107.50M+53.8%
FY2021Dec 31, 2021$69.89M+538.0%
FY2020Dec 31, 2020$10.95M–
FY2019Dec 31, 2019-$39.00K–
FY2018Dec 31, 2018-$8.62M–
FY2017Dec 31, 2017-$1.27M-108.3%
FY2016Dec 31, 2016$15.38M–
FY2015Dec 31, 2015-$6.90M–
FY2014Dec 31, 2014-$17.98M-202.8%
FY2013Dec 31, 2013$17.49M-31.1%
FY2012Dec 31, 2012$25.40M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$39.73M-5.8%
Q1 FY2026Mar 31, 2026$13.63M-63.5%
Q4 FY2025Dec 31, 2025$35.61M-21.1%
Q3 FY2025Sep 30, 2025$25.32M-55.6%
Q2 FY2025Jun 30, 2025$42.18M-23.6%
Q1 FY2025Mar 31, 2025$37.29M-22.3%
Q4 FY2024Dec 31, 2024$45.14M-16.4%
Q3 FY2024Sep 30, 2024$57.05M-21.5%
Q2 FY2024Jun 30, 2024$55.22M+49.7%
Q1 FY2024Mar 31, 2024$48.01M+43.6%
Q4 FY2023Dec 31, 2023$53.98M+42.7%
Q3 FY2023Sep 30, 2023$72.68M+212.9%
Q2 FY2023Jun 30, 2023$36.90M+48.6%
Q1 FY2023Mar 31, 2023$33.43M+54.7%
Q4 FY2022Dec 31, 2022$37.83M+56.0%
Q3 FY2022Sep 30, 2022$23.23M-6.2%
Q2 FY2022Jun 30, 2022$24.82M+135.1%
Q1 FY2022Mar 31, 2022$21.61M+109.7%
Q4 FY2021Dec 31, 2021$24.25M+742.4%
Q3 FY2021Sep 30, 2021$24.77M+604.3%
Q2 FY2021Jun 30, 2021$10.56M–
Q1 FY2021Mar 31, 2021$10.31M+37.8%
Q4 FY2020Dec 31, 2020$2.88M–
Q3 FY2020Sep 30, 2020$3.52M+46.3%
Q2 FY2020Jun 30, 2020-$2.92M-400.3%
Q1 FY2020Mar 31, 2020$7.48M–
Q4 FY2019Dec 31, 2019-$244.00K-115.8%
Q3 FY2019Sep 30, 2019$2.40M-5.7%
Q2 FY2019Jun 30, 2019$973.00K–
Q1 FY2019Mar 31, 2019-$3.17M–
Q4 FY2018Dec 31, 2018$1.55M–
Q3 FY2018Sep 30, 2018$2.55M–
Q2 FY2018Jun 30, 2018-$2.94M-234.6%
Q1 FY2018Mar 31, 2018-$9.78M-796.4%
Q4 FY2017Dec 31, 2017-$1.75M–
Q3 FY2017Sep 30, 2017-$2.94M-150.8%
Q2 FY2017Jun 30, 2017$2.19M–
Q1 FY2017Mar 31, 2017$1.40M–
Q4 FY2016Dec 31, 2016-$4.83M–
Q3 FY2016Sep 30, 2016$5.80M–

More Amphastar Pharmaceuticals figures

See a number that looks wrong?